Eszopiclone
Eszopiclone is a nonbenzodiazepine hypnotic indicated for the treatment of insomnia. As a cyclopyrrolone derivative, it selectively binds to GABA-A receptors to promote sleep initiation and maintenance while having less impact on sleep architecture compared to traditional benzodiazepines.
Clinical Overview
Primary Clinical Applications
Eszopiclone is effective for both sleep onset and sleep maintenance insomnia. It has been studied for long-term use (up to 6 months) and may be appropriate for chronic insomnia when non-pharmacological interventions are insufficient. It provides 7-8 hours of sleep without significant next-day impairment.
Mechanism and Sleep Benefits
Eszopiclone acts as a positive allosteric modulator of GABA-A receptors, particularly those containing alpha-1 subunits. This selective binding promotes sleep while preserving normal sleep stages and reducing rebound insomnia compared to traditional sedative-hypnotics.
Clinical Considerations
The medication should be taken immediately before bedtime with at least 7-8 hours available for sleep. It has a relatively short half-life (6 hours) which minimizes next-day sedation. Tolerance and dependence potential exists but may be lower than traditional benzodiazepines.
Key Clinical Points
Complex sleep behaviours occur without alcohol
Sleep-driving and sleep-eating have been reported in the absence of alcohol or other CNS depressants. Any such episode warrants immediate discontinuation rather than dose reduction.
Next-day impairment is dose-related
Risk rises appreciably at 2 to 3 mg. Patients should be cautioned about driving and other activities requiring alertness the following morning, particularly at the higher doses.
Studied for longer-term use
Unlike most hypnotics, eszopiclone has trial data extending to six months, which makes it a more defensible option where chronic insomnia has not responded to non-pharmacological measures.
High-fat meals blunt absorption
Taking it with or shortly after a fatty meal delays onset and reduces peak concentration, which patients often misread as loss of efficacy.
Metallic taste is the signature side effect
An unpleasant metallic taste is among the most commonly reported effects and a frequent reason for discontinuation. Elderly patients cap at 2 mg, and 1 mg in severe hepatic impairment or with strong CYP3A4 inhibitors.
Prescribing Information
Dosing & Administration
Insomnia – Adults:
- Initial: 1 mg immediately before bedtime
- Range: 1-3 mg once daily
- Maximum: 3 mg once daily
- Sleep duration required: 7-8 hours
Elderly (≥65 years):
- Initial and maximum: 1 mg immediately before bedtime
- Sleep maintenance difficulty: May increase to 2 mg if needed
Hepatic Impairment:
- Severe impairment: 1 mg immediately before bedtime
Administration:
- Take immediately before bedtime
- Ensure 7-8 hours available for sleep
- Do not take with or after a high-fat meal
Indications
- Treatment of insomnia
- Difficulty with sleep onset and/or sleep maintenance
Contraindications
- Hypersensitivity to eszopiclone or any component
- No absolute contraindications
Warnings & Precautions
- Complex sleep behaviors: Sleep-driving, sleep-eating, and other activities while not fully awake may occur without alcohol or other CNS depressants; discontinue immediately if these occur
- CNS depression: Risk increased with alcohol and other CNS depressants
- Next-day impairment: Dose-dependent risk, especially at ≥2–3 mg; use caution with activities requiring alertness the next day
- Dependence and withdrawal: Risk with prolonged use
- Suicidal ideation: Monitor for mood changes
- Respiratory depression: Risk in patients with compromised respiratory function
Drug Interactions
- CNS depressants: Enhanced sedation and respiratory depression
- Alcohol: Contraindicated – dangerous potentiation
- Strong CYP3A4 inhibitors: Reduce eszopiclone dose to 1 mg
- CYP3A4 inducers: May reduce eszopiclone effectiveness
Adverse Reactions
Common (≥2%):
- Unpleasant taste (metallic), headache, somnolence
- Dizziness, dry mouth, dyspepsia
Serious:
- Complex sleep behaviors, severe allergic reactions
- Depression, suicidal ideation
Special Populations
- Elderly: Increased sensitivity, maximum 2 mg daily
- Hepatic Impairment: Severe impairment maximum 1 mg daily
- Pregnancy: Category C – use only if benefits outweigh risks
- Dependence Risk: Limit duration when possible, taper gradually
Frequently Asked Questions
What is Eszopiclone used for?
Eszopiclone is a nonbenzodiazepine hypnotic indicated for the treatment of insomnia. As a cyclopyrrolone derivative, it selectively binds to GABA-A receptors to promote sleep initiation and maintenance while having less impact on sleep architecture compared to traditional benzodiazepines.
What class of drug is Eszopiclone?
Eszopiclone is classified as: Nonbenzodiazepine Hypnotic (Z-drug).
Complex sleep behaviours occur without alcohol?
Sleep-driving and sleep-eating have been reported in the absence of alcohol or other CNS depressants. Any such episode warrants immediate discontinuation rather than dose reduction.
Next-day impairment is dose-related?
Risk rises appreciably at 2 to 3 mg. Patients should be cautioned about driving and other activities requiring alertness the following morning, particularly at the higher doses.
Studied for longer-term use?
Unlike most hypnotics, eszopiclone has trial data extending to six months, which makes it a more defensible option where chronic insomnia has not responded to non-pharmacological measures.
High-fat meals blunt absorption?
Taking it with or shortly after a fatty meal delays onset and reduces peak concentration, which patients often misread as loss of efficacy.
Source: FDA prescribing information (DailyMed)